Apollomics Inc. Warrant
APLMWStock
$0.01−46.92%52W
Market Cap—
P/E—
Div yield—
Beta1.18
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-63.61%
Price vs S&P 500 (4W)-18.80%
VGM Score20.13
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APLMWApollomics Inc. Warrant | — | — | D | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Apollomics Inc is a clinical-stage biopharmaceutical company developing oncology therapies that target molecular pathways and enhance immune response. Its lead candidates include vebreltinib, a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan, an E-Selectin antagonist designed for use with chemotherapy in acute myeloid leukemia.